Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx Biopharma has announced that all outstanding legal issues between Hemispherx and Bioclones and Ribotech have been resolved and that all litigation between the companies is in the process of being dismissed by mutual agreement.
Subscribe to our email newsletter
Additionally, based on current discussions, Hemispherx management sees the potential for a mutually beneficial new Ampligen partnership with the principals now controlling Bioclones and Ribotech.
As part of the settlement, Hemispherx has regained all marketing rights to Ampligen which had been previously granted to Bioclones for Great Britain, the Republic of Ireland, Australia, New Zealand, Tasmania, Madagascar, Mauritius, Reunion, Indonesia, Papua New Guinea and all nations on the continents of Africa and South America.
In October 1994, Hemispherx entered into a licensing and marketing agreement with Bioclones, a South Africa-based biopharmaceutical company, with respect to co-development of various RNA drugs, including Hemispherx’s lead investigational drug, Ampligen.
Pursuant to the 1994 agreement a subsidiary, Ribotech was created for pharmaceutical manufacturing utilizing recombinant DNA technology. Subsequently, Hemispherx deemed the 1994 agreement void due to alleged failures of performance by Bioclones.